Toxoplasma gondii is an intracellular protozoan parasite that causes toxoplasmosis. This parasite is an opportunistic pathogen that infects all warm blood animals including humans (
1). It has been estimated that up to one third of the world’s population are infected by
T. gondii. Despite the worldwide distribution and prevalence of
T. gondii infection, it is usually mild and self-limiting in immunocompetent hosts (
2-
6). However, toxoplasmosis can cause severe and fatal disease in immunocompromised patients and congenitally infected fetuses and newborns (
2,
7-
9). It has been proven that there are 3 principle routes for
Toxoplasma transmission: (1) the consumption of oocysts contaminated water or vegetables, (2) ingestion of raw/undercooked meat containing tissue cysts, and (3) congenital transmission (
1,
10). Furthermore, toxoplasmosis is considered as one of the transfusion-transmissible diseases and in rare cases can be transmitted through an organ transplant or blood transfusion.
T. gondii is capable to invade and replicate in all nucleated cells of the body and survive for several weeks in stored blood (
11-
14). Today, there has been a significant reduction in the number of transfusion- transmitted infections; however, screening for
T. gondii in blood and blood product is not obligatory, and subsequently blood borne toxoplasmosis remain a concern (
1,
9,
11). Considering the serious consequences of toxoplasmosis in immunocompromised individuals (such as patients with acquired immunodeficiency syndrome and transplant recipients) and neglecting the
T. gondii infection monitoring in blood donors, it is of paramount importance to have knowledge about the
T. gondii prevalence in blood donor population for provision of safe blood and blood products (
2,
9-
11). Besides, to date, there has been no recommended guideline or procedure for the prevention of transfusion- transmitted toxoplasmosis.